AIHTA - Publications - Search - Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)

Rothschedl, E. and Wolf, S. (2023): Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Oncology Fact Sheet Nr. 118.

[thumbnail of Oncology Fact Sheet Nr.118.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
843kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 700-770 Liver. Billary tract
Language:English
Series Name:Oncology Fact Sheet Nr. 118
Deposited on:01 Feb 2023 15:39
Last Modified:01 Feb 2023 15:50

Repository Staff Only: item control page